PL3609486T3 - Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssaków - Google Patents
Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssakówInfo
- Publication number
- PL3609486T3 PL3609486T3 PL18716625T PL18716625T PL3609486T3 PL 3609486 T3 PL3609486 T3 PL 3609486T3 PL 18716625 T PL18716625 T PL 18716625T PL 18716625 T PL18716625 T PL 18716625T PL 3609486 T3 PL3609486 T3 PL 3609486T3
- Authority
- PL
- Poland
- Prior art keywords
- sarpogrelate
- mammals
- treatment
- heart disease
- heart
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17165863 | 2017-04-11 | ||
| EP17180011 | 2017-07-06 | ||
| PCT/EP2018/059295 WO2018189246A1 (en) | 2017-04-11 | 2018-04-11 | Method for the treatment of heart disease in mammals |
| EP18716625.1A EP3609486B1 (en) | 2017-04-11 | 2018-04-11 | Sarpogrelate for use in a method for the treatment of heart disease in mammals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3609486T3 true PL3609486T3 (pl) | 2021-11-29 |
Family
ID=61913190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18716625T PL3609486T3 (pl) | 2017-04-11 | 2018-04-11 | Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssaków |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11116741B2 (pl) |
| EP (1) | EP3609486B1 (pl) |
| JP (1) | JP7148545B2 (pl) |
| CN (1) | CN110913846B (pl) |
| AU (1) | AU2018253371B2 (pl) |
| BR (1) | BR112019021344A2 (pl) |
| CA (1) | CA3059512A1 (pl) |
| DK (1) | DK3609486T3 (pl) |
| ES (1) | ES2886045T3 (pl) |
| HU (1) | HUE055319T2 (pl) |
| LT (1) | LT3609486T (pl) |
| PL (1) | PL3609486T3 (pl) |
| WO (1) | WO2018189246A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102707874B1 (ko) * | 2021-10-27 | 2024-09-25 | 주식회사 메디테이크 | 안지오텐신 수용체 차단제 및 sglt2 억제제를 포함하는 복합 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893050B2 (en) | 2005-10-26 | 2011-02-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| KR20080072579A (ko) | 2007-02-02 | 2008-08-06 | 미쓰비시 타나베 파마 코퍼레이션 | 비만 예방 및/또는 치료약 |
| GB0715047D0 (en) * | 2007-08-02 | 2007-09-12 | Glaxo Group Ltd | Novel Compounds |
| US9808529B2 (en) | 2012-05-18 | 2017-11-07 | Luoda Pharma Pty Ltd | Liquid formulation |
| CA2895829A1 (en) | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | Novel methysergide derivatives |
| WO2016121738A1 (ja) | 2015-01-27 | 2016-08-04 | 国立大学法人山梨大学 | シロスタゾールの薬効評価方法 |
-
2018
- 2018-04-11 CN CN201880030993.3A patent/CN110913846B/zh active Active
- 2018-04-11 PL PL18716625T patent/PL3609486T3/pl unknown
- 2018-04-11 LT LTEPPCT/EP2018/059295T patent/LT3609486T/lt unknown
- 2018-04-11 BR BR112019021344-9A patent/BR112019021344A2/pt not_active Application Discontinuation
- 2018-04-11 CA CA3059512A patent/CA3059512A1/en active Pending
- 2018-04-11 JP JP2019555629A patent/JP7148545B2/ja active Active
- 2018-04-11 DK DK18716625.1T patent/DK3609486T3/da active
- 2018-04-11 ES ES18716625T patent/ES2886045T3/es active Active
- 2018-04-11 HU HUE18716625A patent/HUE055319T2/hu unknown
- 2018-04-11 AU AU2018253371A patent/AU2018253371B2/en active Active
- 2018-04-11 EP EP18716625.1A patent/EP3609486B1/en active Active
- 2018-04-11 WO PCT/EP2018/059295 patent/WO2018189246A1/en not_active Ceased
- 2018-04-11 US US16/604,575 patent/US11116741B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018253371A1 (en) | 2019-10-31 |
| HUE055319T2 (hu) | 2021-11-29 |
| JP7148545B2 (ja) | 2022-10-05 |
| BR112019021344A2 (pt) | 2020-06-16 |
| JP2020513028A (ja) | 2020-04-30 |
| CN110913846A (zh) | 2020-03-24 |
| LT3609486T (lt) | 2021-10-11 |
| EP3609486B1 (en) | 2021-06-02 |
| WO2018189246A1 (en) | 2018-10-18 |
| CN110913846B (zh) | 2023-04-04 |
| US20200297685A1 (en) | 2020-09-24 |
| DK3609486T3 (da) | 2021-08-16 |
| ES2886045T3 (es) | 2021-12-16 |
| US11116741B2 (en) | 2021-09-14 |
| CA3059512A1 (en) | 2018-10-18 |
| EP3609486A1 (en) | 2020-02-19 |
| AU2018253371B2 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA193734S (en) | Skin massager | |
| CA196431S (en) | Skin massager | |
| CA193621S (en) | Skin massager | |
| IL272300A (en) | Mavacamten for use in the treatment of hypertrophic cardiomyopathy | |
| IL256175A (en) | Using exosomes to treat the disease | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| HUE059752T2 (hu) | A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek | |
| PT3600415T (pt) | Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca | |
| SI3592355T1 (sl) | KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze | |
| IL254496B (en) | Treatment of type 2 diabetes patients | |
| IL254500A0 (en) | Treatment of patients with type 2 diabetes | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| SG11202010802PA (en) | Treatment plan facilitator | |
| GB2575031B (en) | Skin treatment apparatus | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL273563A (en) | A physiological compound for use in the treatment of osteoarthritic pain | |
| LT3609486T (lt) | Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui | |
| IL272422A (en) | Methods for treating diseases of the meninges | |
| PL3710043T3 (pl) | Fgf10 do leczenia chorób serca | |
| PT3609486T (pt) | Sarpogrelato para uso num método para o tratamento de doença cardíaca em mamíferos | |
| IL246608A0 (en) | Preparations and methods for treating heart disease | |
| IL268265B (en) | 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment | |
| GB201819776D0 (en) | Medical process | |
| GB201811912D0 (en) | Treatment of disease | |
| GB201811911D0 (en) | Treatment of disease |